william bailey - wall st finance

Prima (ASX Code: PRR) has been buoyed by the progress of NASDAQ listed company Dendreon, who like Prima, is developing a cancer immune therapy Dendreon's treatment is targeted at prostate Cancer and earlier this month it concluded its Pivotal Phase Trial on its product, which is called Provenge


Dendreon's market capitalisation has grown from US$ 6OOm to over US$ 2Bn over the last month It share price has risen sharply in recent weeks in anticipation of the successful completion of its Pivotal Clinical Trial, which paves the way for it to achieve commercialisation and become the world’s first US FDA approved Cancer vaccine immuno-therapy

Prima BioMed Shares at 6.5 cents Aussie. They are well worth buying with all that is happening with the FDA trials and the Patent approvals.



Regards



Wall Street Finance

WSL Web Page